Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556476 | 0.84 | HSD11B1 (0.43) | HSD11B1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL24105916 | 0.82 | HSD11B1 (0.40) | HSD11B1EPHX2L3MBTL1CHRNB2CHRNB4 | |
| SCHEMBL13609189 | 0.82 | KMT2A (0.47) | HSD11B1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL21376619 | 0.79 | HSD11B1 (0.47) | HSD11B1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL11076676 | 0.76 | HSD11B1 (0.54) | HSD11B1EPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL20665988 | 0.73 | DPP4 (0.36) | FPR3FPR2DPP4PREPFAP | |
| SCHEMBL21376258 | 0.73 | EPHX2 (0.46) | HSD11B1EPHX2L3MBTL1 | |
| SCHEMBL24105941 | 0.71 | MTNR1A (0.36) | EPHX2NPC1RAB9ADPP4PREP | |
| SCHEMBL12919905 | 0.71 | EPHX2 (0.61) | HSD11B1EPHX2L3MBTL1NPC1 | |
| SCHEMBL7719165 | 0.70 | HSD11B1 (0.42) | HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | HSD11B1 3214/4885EPHX2 1146/4885L3MBTL1 1683/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | HSD11B1 3214/4885EPHX2 1146/4885L3MBTL1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.